Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down on Insider Selling

Kymera Therapeutics, Inc. (NASDAQ:KYMR) gapped down before the market opened on Tuesday after an insider sold shares in the company. The stock had previously closed at $94.30, but opened at $90.72. Kymera Therapeutics shares last traded at $88.2150, with a volume of 838,147 shares changing hands.

Specifically, insider Jared Gollob sold 49,307 shares of Kymera Therapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $88.67, for a total value of $4,372,051.69. Following the completion of the transaction, the insider owned 109,992 shares of the company’s stock, valued at approximately $9,752,990.64. The trade was a 30.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Nello Mainolfi sold 100,000 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $89.17, for a total transaction of $8,917,000.00. Following the sale, the chief executive officer directly owned 660,482 shares in the company, valued at approximately $58,895,179.94. The trade was a 13.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In related news, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $89.76, for a total value of $448,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on KYMR. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Bank of America boosted their price target on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday. HC Wainwright increased their price objective on shares of Kymera Therapeutics from $84.00 to $134.00 and gave the company a “buy” rating in a report on Tuesday. BTIG Research set a $138.00 target price on shares of Kymera Therapeutics in a research report on Monday. Finally, Leerink Partners upped their price target on shares of Kymera Therapeutics from $70.00 to $118.00 and gave the stock an “outperform” rating in a research report on Monday. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $101.35.

Kymera Therapeutics Price Performance

The stock has a market capitalization of $6.33 billion, a PE ratio of -24.43 and a beta of 2.28. The company’s 50 day moving average price is $62.19 and its two-hundred day moving average price is $50.50.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The business had revenue of $2.76 million during the quarter, compared to analysts’ expectations of $23.15 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%. Analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC grew its holdings in Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after buying an additional 540 shares in the last quarter. Larson Financial Group LLC raised its holdings in shares of Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after acquiring an additional 349 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after acquiring an additional 770 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of Kymera Therapeutics by 652.0% in the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after purchasing an additional 815 shares during the period. Finally, Osaic Holdings Inc. increased its position in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.